Real-world experiences with ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc- Von Willebrand Factor XTEN Fusion Protein]: A first-in-class treatment option (Sponsored by Sanofi)

  Thursday, April 4, 2024           12:45 PM - 1:45 PM ET

Description

Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective.